×
About 3,580 results

ALLMedicine™ Bacterial Pneumonia Center

Research & Reviews  1,043 results

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
https://clinicaltrials.gov/ct2/show/NCT03969901

Jun 30th, 2022 - The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. Partici...

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
https://clinicaltrials.gov/ct2/show/NCT03583333

Jun 28th, 2022 - This study will evaluate the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) (MK-7655A) compared to piperacillin/tazobactam (PIP/TAZ) in the treatment of adults diagnosed with Hospital-Acquired Bacterial Pneumonia (HABP) or Ventila...

Characteristics and Results of Hospital Admission Caused by Influenza Virus Infections ...
https://doi.org/10.1093/tropej/fmac049
Journal of Tropical Pediatrics; Üzüm Ö, Karadağ Öncel E et. al.

Jun 26th, 2022 - The influenza virus is an infectious disease with acute respiratory tract infections, caused secondary bacterial infections and death. In this study, we aimed to determine which predictors were associated with the need for high-flow nasal cannula ...

Major candidate variables to guide personalised treatment with steroids in critically i...
https://doi.org/10.1007/s00134-022-06726-w 10.1016/j.chest.2020.10.054 10.1503/cmaj.200645 10.1016/S2213-2600(19)30417-5 10.1097/CCE.0000000000000111 10.1164/rccm.201706-1172OC 10.1093/cid/ciaa478 10.1056/NEJMoa2021436 10.1001/jama.2020.17023 10.1183/13993003.00048-2021 10.1183/13993003.00979-2021 10.1371/journal.pone.0255644 10.1097/00003246-200208000-00016 10.1001/jama.2015.88 10.1016/j.ebiom.2017.09.023 10.1001/jama.2021.18295 10.1007/s00134-017-4919-5 10.1183/13993003.00582-2017 10.1186/s13054-021-03727-x 10.1007/978-1-4899-3115-3 10.1093/biomet/70.1.41 10.1080/00273171.2011.568786 10.1093/aje/kwj149 10.1161/CIRCULATIONAHA.115.017719 10.1214/aos/1176350951 10.1093/aje/kwf215 10.1136/bmj.b2393 10.1007/s00134-021-06394-2 10.1016/j.cmi.2021.11.007 10.1016/j.chest.2020.11.049 10.1186/s13613-021-00951-0 10.1016/j.arbres.2021.10.001 10.1186/s13054-020-03422-3 10.1007/s00134-020-06311-z 10.1186/s13054-020-03400-9 10.1016/j.chest.2021.04.002 10.1007/s00134-020-06289-8 10.1007/s00134-021-06394-2 10.1186/s13054-021-03588-4 10.1097/CCM.0b013e31819d2b43 10.1097/CCM.0000000000003021 10.1164/rccm.202105-1302OC
Intensive Care Medicine; Torres A, Motos A et. al.

Jun 22nd, 2022 - Although there is evidence supporting the benefits of corticosteroids in patients affected with severe coronavirus disease 2019 (COVID-19), there is little information related to their potential benefits or harm in some subgroups of patients admit...

New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
https://doi.org/10.1128/aac.00256-22
Antimicrobial Agents and Chemotherapy; O'Donnell JN, Lodise TP

Jun 22nd, 2022 - Imipenem (IMI)/cilastatin/relebactam (REL) (I/R) is a novel β-lactam/β-lactamase inhibitor combination with expanded microbiologic activity against carbapenem-resistant non-Morganellaceae Enterobacterales (CR-NME) and difficult-to-treat (DTR) Pseu...

see more →

Drugs  81 results see all →

Clinicaltrials.gov  109 results

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
https://clinicaltrials.gov/ct2/show/NCT03969901

Jun 30th, 2022 - The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. Partici...

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
https://clinicaltrials.gov/ct2/show/NCT03583333

Jun 28th, 2022 - This study will evaluate the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) (MK-7655A) compared to piperacillin/tazobactam (PIP/TAZ) in the treatment of adults diagnosed with Hospital-Acquired Bacterial Pneumonia (HABP) or Ventila...

Antibiotic Therapy in Viral Airway Infections
https://clinicaltrials.gov/ct2/show/NCT05045612

Jun 21st, 2022 - In patients with positive airway sample for respiratory viruses, the investigators hypothesize that discontinuation of antibiotic therapy is safe and non-inferior to continuation of antibiotic therapy. More specifically, the investigators hypothes...

Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
https://clinicaltrials.gov/ct2/show/NCT03996967

May 31st, 2022 - Clinical pneumonia is a leading cause of pediatric hospitalization. The etiology is generally bacterial or viral. Prompt and optimal treatment of pneumonia is critical to reduce mortality. However, adequate pneumonia management is hampered by: a) ...

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST)
https://clinicaltrials.gov/ct2/show/NCT03042143

May 25th, 2022 - The role of MSCs as a novel treatment in ARDS. Mesenchymal Stem Cells (MSCs) are a mononuclear cell population that have the potential to differentiate into multiple lineages, and bone, cartilage and adipocyte cells in particular. Cell-based thera...

see more →

News  195 results

COVID-19 Tied to Increased Risk for Alzheimer's, Parkinson's Disease
https://www.medscape.com/viewarticle/976244

Jun 27th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. COVID-19 has been associated with a threefold increased risk of Alzheimer's disease (AD) and a doubling of Parkinson's disease (PD) risk, a new st...

52-year-old man • hematemesis • history of cirrhosis • persistent fevers • Dx?
https://www.mdedge.com/familymedicine/article/253717/addiction-medicine
MDedge Family Medicine; Nathan Yee, MD, Blake A. Mann, MD et. al.

Apr 13th, 2022 - THE CASE A 52-year-old man presented to the emergency department after vomiting a large volume of blood and was admitted to the intensive care unit. His past medical history was remarkable for untreated chronic hepatitis C resulting from injection.

Clinical Edge Journal Scan Commentary: CAP January 2022
https://www.mdedge.com/chestphysician/article/250325/community-acquired-pneumonia/clinical-edge-journal-scan-commentary-cap
Russell W. Steele, MD, MDedge News

Jan 2nd, 2022 - [[{"fid":"282102","view_mode":"medstat_image_flush_left","fields":{"format":"medstat_image_flush_left","field_file_image_caption[und][0][value]":"","field_file_image_caption[und][0][format]":"filtered_html","field_file_image_credit[und][0][value]".

Most community-acquired bacterial pneumonia-causing pathogens succumb to lefamulin
https://www.mdedge.com/chestphysician/article/250228/community-acquired-pneumonia/most-community-acquired-bacterial

Dec 25th, 2021 - Key clinical point: Lefamulin is suitable as monotherapy against common community-acquired bacterial pneumonia ( CABP)-causing pathogens, both typical and atypical, including drug-resistant strains and those causing polymicrobial infections. Main.

High-Flow Surpasses Low-Flow Oxygen for COVID-19
https://www.medscape.com/viewarticle/964399

Dec 8th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. COVID-19 patients with severe disease were significantly less likely to require mechanical ventilation when treated with high-flow oxygen therapy ...

see more →

Patient Education  4 results see all →